BCL2 and acute myeloid leukemia: Genomes of acute myeloid leukemia (AML) cells resistant to the BCL-2–selective inhibitor venetoclax (VEN) show extensive differential methylation with the activation of the RAS/MAPK pathway, leading to increased stability and higher levels of MCL-1 protein.